Corrects name of unit in headline, paragraphs 1 and 4 to biosciences and diagnostic solutions from life sciences. The error also appeared in an earlier version of the story
Feb 5 (Reuters) - Becton Dickinson BDX.N beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device maker aims to focus on its core business.
"We believe the separation will position New BD as a differentiated MedTech leader and enable optimized investment," said CEO Tom Polen.
The company expects to announce more details on the separation plans by the end of fiscal 2025.
Becton's biosciences and diagnostic solutions unit makes diagnostic products such as those used to detect infectious diseases and cancers.
Earlier this week, the Financial Times reported activist investor Starboard Value had taken a stake in Becton and was pushing the company to sell its life sciences unit.
The company also raised the lower end of its fiscal 2025 profit forecast to a range of $14.30 to $14.60 per share, compared to the previous range of $14.25 to $14.60 each.
Becton's total sales for the reported quarter came in at $5.17 billion, above analysts' estimates of $5.1 billion, according to data compiled by LSEG.
On an adjusted basis, the company reported a per-share profit of $3.43, beating analysts' average expectation of $2.98.
(Reporting by Kamal Choudhury, Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Alan Barona)
((Kamal.Choudhury@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。